Microbix Biosystms J (TSE:MBX)
TSX:MBX
Want to see TSE:MBX full AI Analyst Report?
MBX Stock Chart & Stats
C$0.24
-C$0.01(-2.33%)
At close: 4:00 PM EST
C$0.24
-C$0.01(-2.33%)
Day’s Range― - ―
52-Week RangeC$0.21 - C$0.34
Previous CloseN/A
Volume37.35K
Average Volume (3M)57.61K
Market Cap
C$37.41M
Enterprise ValueC$36.07M
Total Cash (Recent Filing)C$8.13M
Total Debt (Recent Filing)C$6.80M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding138,553,380
10 Day Avg. Volume59,614
30 Day Avg. Volume57,610
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.33
Price to Sales (P/S)1.98
P/FCF Ratio-42.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.40Price Target Upside66.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business DiversificationDiversifying antigen sales into additional markets reduces reliance on a few regions and could stabilize revenue when demand patterns shift.
Earnings BeatQuarterly results beat analyst estimates, indicating stronger-than-expected operational performance that could lead analysts to raise near-term outlooks.
Organic Revenue Strength Excluding Major ClientsSales excluding two major clients increased year over year, signaling underlying demand resilience outside the largest accounts.
Bears Say
China Demand WeaknessReduced shipments into China due to a milder respiratory season have weakened antigen revenue and could pressure overall top-line recovery.
Customer Concentration RiskRevenue is exposed to disruptions at a small number of large clients, creating outsized downside when those customers encounter operational problems.
Inventory Overhang Delaying RecoveryCustomers working through existing inventories are likely to postpone new purchases, creating an inventory overhang that could slow the rebound in organic growth.
Microbix Biosystms News
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.21 and its highest was C$0.34 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Microbix Biosystms J’s market cap is C$37.41M.
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is Aug 13, 2026 which is in 65 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on May 14, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 138,553,380 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Microbix Biosystms J
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
MBX Stock 12 Month Forecast
Average Price Target
C$0.40
▲(66.67% Upside)
Technical Analysis
BriaCell Therapeutics
―
Resverlogix
―
Devonian Health Group
―
Defence Therapeutics
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---